Nundina › Kalender entdecken › FDA-Zulassungen neuer Arzneimittel-Kalender › FDA approves Emcitate (tiratricol)FDA approves Emcitate (tiratricol)28. September 2026The FDA approved Emcitate (tiratricol), a drug from Rare Thyroid. Form: Tablet, For Suspension, Oral. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application NDA220963.FDA-Zulassungen neuer Arzneimittel-KalenderMehr aus diesem Kalender

20. Oktober 2026 - FDA approves Hibsago (bepirovirsen)

19. Oktober 2026 - FDA approves Calrezdy (calcuim chloride)

19. Oktober 2026 - FDA approves Cienby (sodium ctirate)

16. Oktober 2026 - FDA approves Yulzety (rivaroxaban)

16. Oktober 2026 - FDA approves Brytly (brytly (apraclonidine))